With the ability to detect over 70 types of cancer via the presence of Circulating Tumour Cells (CTCs), TruCheck is revolutionising the field of early cancer detection.
The TruCheck test does not detect all cancer types and not all cancer types can be detected in the blood. False negative and false positive results do occur.
TruCheck is a pioneering screening test that identifies cancer at its earliest stages, often before symptoms emerge, making it potentially more treatable. Regular cancer screenings are crucial even if you are feeling healthy.
TruCheck identifies a common cancer signal across numerous cancer types, inclusive of those not routinely screened in today’s practice, enabling treatment at earlier stages.
The test only requires a single blood draw. We will arrange a trained professional to visit you to take a sample. We make the process as simple and convenient as possible.
If you receive a positive analysis, the test can identify where in the body the cancer is located. This gives you the best possible chance to treat the cancer early.
Small text below boxes, change to ‘The TruCheck test looks for signals related to active cancer and does not predict your future genetic predisposition for cancer.
TruCheck is an advanced non-invasive blood test which provides evidence of an underlying malignancy via a safe, simple and quick blood draw. TruCheck evaluates blood sample to detect ‘Circulating Tumour Cells’ (CTCs), which are cancer cells that escape from the tumour and enter the blood stream. TruCheck enriches these CTCs from the blood sample and confirms their identity via a process called ‘Immunocytochemistry’ (ICC). A positive CTC finding is indicative of the presence of an underlying cancer whereas when CTCs are undetectable, the patient may not have a cancer.
TruCheck detects CTCs, which are known to be present (and detected ubiquitously) in most types of cancers called solid tumours. Several prior clinical studies have shown that CTCs are detectable even in very early Stage 0 (in situ cancer) as well as Stage I and Stage II. CTCs are detected across all solid organ tumor types and subtypes, in men and women. CTCs do not exist in individuals without cancer. CTCs are undetectable in the blood of patients with non-cancerous (benign) tumours. Thanks to these properties, CTCs have high accuracy for cancer detection.
You can start by requesting the test online by clicking Get Started. You will be guided through a number of questions to determine your eligibility for the test. Your request will then be reviewed to ensure that the test is suitable for you.
We need to complete a simple blood draw from you which will then be analysed in the laboratory. We have trained professionals covering the whole UK who can visit you in your home or office to do this, so you don’t need to travel anywhere.
Your results will be ready about two weeks after your appointment. We will provide guidance on your next steps if you receive a positive result.
There are three possible results:
– Positive for malignancy: CTCs were detected in the blood sample. The analysis suggests the likely organ of origin and malignancy type.
– Negative for malignancy: CTCs are not detected in the given sample. The chance of
having an active malignancy present in the body is low.
– Indeterminate: CTCs were detected in the given blood sample; however, type of malignancy or organ of origin could not be determined. A recollection of a blood sample is required to determine result (free of charge).
Please note, TruCheck is a screening test and does not diagnose cancer itself. While it offers a ground-breaking tool for early detection, additional diagnostic testing is necessary to confirm a cancer diagnosis. Furthermore, TruCheck is not a genetic risk assessment tool and does not predict future risk of developing cancer. It operates by detecting existing cancer signals, not potential genetic predispositions.
The TruCheck test is suggested for use in adults with a higher risk of cancer, typically those aged 50 or above. TruCheck does not detect all types of cancers and should be considered a supplemental tool alongside routine cancer screening tests advised by your healthcare provider. The primary goal of TruCheck is to identify cancer signals and predict their origin within the body. It is not recommended for use in individuals who are pregnant, under the age of 40, or currently undergoing active cancer treatment.
Results must be analysed by a healthcare professional, taking into account the patient’s medical history, clinical signs, and symptoms. A result of “No Cancer Signal Detected” does not definitively exclude the presence of cancer. Likewise, a “Cancer Signal Detected” result necessitates further diagnostic evaluation through established medical procedures (such as imaging) to confirm the presence of cancer.
In cases where further testing does not confirm cancer, this could indicate either the absence of cancer or that the test was unable to detect it, including situations where the cancer is located in a different part of the body. Be aware that false-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) results can occur.
1. Akolkar et al. B15: Circulating tumor cells express tissue specific antigens in multiple cancers. Clin Cancer Res.2020;
26(11_Suppl). DOI: 10.1158/1557-3265.LiqBiop20-B15.
2. Akolkar et al. Circulating ensembles of tumor-associated cells: A redoubtable new systemic hallmark of cancer. Int. J.
Cancer:2019; 146, 3485-3494. DOI: 10.1002/ijc.32815.
3. Gaya A et al. Evaluation of circulating tumor cell clusters for pan-cancer noninvasive diagnostic triaging. Cancer Cytopathol.
2020; 129 (3) 226-238 doi: 10.1002/cncy.22366.
4. Ranade A et al. Hallmark Circulating Tumor-Associated Cell Clusters Signify 230 Times Higher One-Year Cancer Risk. Cancer
Prev Res. 2021;14:11-6 DOI:10.1158/1940-6207.CAPR-20-0322.
5. Crook T et al. Accurate Screening for Early-Stage Breast Cancer by Detection and Profiling of Circulating Tumor Cells. Cancers
(Basel). 2022 Jul; 14(14): 3341. DOI: 10.3390/cancers14143341.
